Complex Information for Anesthesiologists Presented Quickly and Clearly
*ENIGMA II trial cardiac risk factors included history of coronary artery disease, heart failure, cerebrovascular disease, or peripheral vascular disease, or age ≥70 yr with other comorbiditiesInfographic created by Holly B. Ende, Vanderbilt University Medical Center; James P. Rathmell, Brigham and Women’s Health Care/Harvard Medical School; and Jonathan P. Wanderer, Vanderbilt University Medical Center. Illustration by Annemarie Johnson, Vivo Visuals Studio. Address correspondence to Dr. Ende: holly.ende@vumc.org.
1.
Myles
PS
, Leslie
K
, Chan
MTV
, Forbes
A
, Paech
MJ
, Peyton
P
, Silbert
BS
, Pascoe
E
, and the ENIGMA Trial Group
: Avoidance of nitrous oxide for patients undergoing major surgery.
Anesthesiology
2007
; 107
:221
–31
2.
Myles
PS
, Leslie
K
, Chan
MTV
, Forbes
A
, Peyton
PJ
, Paech
MJ
, Beattie
WS
, Sessler
DI
, Devereaux
PJ
, Silbert
B
, Schricker
T
, Wallace
S
; ANZCA Trials Group for the ENIGMA-II investigators
: The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): A randomised, single-blind trial.
Lancet
2014
; 384
:1446
–54
3.
Peyton
PJ
, Liskaser
G
, Ho
A
, Marsh
H
, Etherington
C
, Torlot
F
, Desai
M
, Perrett
G
, Chee
B
, Leslie
K
, Myles
PS
: Postoperative pulmonary complications in the ENIGMA II Trial: A post hoc analysis.
Anesthesiology
2023
; 138
:354
–63
Copyright © 2023, the American Society of Anesthesiologists. All Rights Reserved.
2023